NCT02846571RecruitingPhase 1/2

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

Source: ClinicalTrials.gov · Last updated 12 Mar 2026

Brief summary (registry, in English)

The intervention in this trial is intraocular islet transplantation. A single dose of 1000 - 3000 Islet Equivalents (IEQ)/kg recipient body weight (BW) will be infused into the anterior chamber of the eye through a self-sealing incision in the peripheral cornea. The procedure is projected to take approximately 20-30 minutes. Transplant recipients in this study will receive localized maintenance immunosuppression via topical application of eye-drops.

Status (registry): Recruiting
Phase (registry): Phase 1/2
Study type: Interventional
Enrollment: 2 (estimated)
First submitted: 18 Jul 2016
Start date: 5 Dec 2019
Primary completion date: 31 Dec 2026
Lead sponsor: Midhat H. Abdulreda
Diseases: Type 1 diabetes, Type 2 diabetes
NCT number: NCT02846571

What you commit to

Study type: Interventional · Phase 1/2
Planned participants: 2
From 5 Dec 2019 to the primary completion date, 31 Dec 2026
2 sites in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Ophthalmic exclusion criteria (only in surgical eye):
Presence of silicone in the anterior segment after complex diabetic retinopathy surgery.
Calculated panel-reactive anti-HLA antibodies \>20%.
Antibodies (i.e., presumed de-novo) to the kidney transplant donor, if applicable.
Invasive aspergillus, histoplasmosis, and coccidioidomycosis infection within one year prior to study enrollment.
Receiving treatment for a medical condition requiring chronic use of systemic steroids, except for the use of ≤5 mg prednisone daily, or an equivalent dose of hydrocortisone, for physiological replacement only.
Use of any investigational agents within 4 weeks of enrollment.
Administration of live attenuated vaccine(s) within 2 months of enrollment.

Other illness

History of uncontrolled glaucoma or glaucoma that had required surgical intervention (e.g., trabeculectomy or shunting devices).
History of allergy to topical steroids and immune-modulatory drugs including CSA and Tacrolimus.
- General and metabolic exclusion criteria:
Active malignancy (cancer) except if successfully treated and declared cancer-free and/or in-remission by the oncologist.
Any medical condition that, in the opinion of the investigator, will interfere with the safe participation in the trial.

Lab values

HbA1c \>10%.
Calculated GFR of ≤40 mL/min/1.73 m2 for patients with kidney transplant or \<80 mL/min/1.73 m2 for those without kidney transplant, using the subject's measured serum creatinine and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation1.
Strict vegetarians (vegans) will be excluded only if their estimated GFR is ≤35 mL/min/1.73 m2 for patients with kidney transplant or \<70 mL/min/1.73 m2 for those without kidney transplant.
Proteinuria (albumin/creatinine ratio or ACr \>300mg/dl) of new onset or since kidney transplantation if applicable.
Presence or history of active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB). Subjects with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection.
Baseline Hb below the lower limits of normal at the local laboratory; lymphopenia (\<1,000/µL), neutropenia (\<1,500/µL), or thrombocytopenia (platelets \<100,000/µL). Participants with lymphopenia are allowed if the investigator determines there is no additional risk with additional clearance from a hematologist.
Severe co-existing cardiac disease, characterized by any one of these conditions:
- Recent myocardial infarction (within past 6 months).
- Evidence of ischemia on functional cardiac exam within the last year.
- Left ventricular ejection fraction \<30%.
Hyperlipidemia despite medical therapy (fasting low-density lipoprotein \[LDL\] cholesterol \>130 mg/dL, treated or untreated; and/or fasting triglycerides \>200 mg/dL) for patients with kidney transplant.

Other

Poor visualization of the anterior chamber (corneal opacity, corneal edema, Herpes Keratitis).
Aphakic status (no lens).
Narrow angle of iris anatomy: Spade Scale IV.
Active uncontrolled uveitis.
Blood Pressure: SBP \>160 mmHg or DBP \>100 mmHg.
Positive crossmatch.
For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study (24 months) or within 4 months after discontinuation, or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable.
Negative screen for Epstein-Barr Virus (EBV) by IgG determination.
Known active alcohol or substance abuse.

Criteria the registry did not label

Patients who meet all of the following criteria are eligible for participation in the study:
Ophthalmic inclusion criteria:
Patient with at least one eye with extensive loss of vision from hand motion to no light perception.
Phakic or pseudophakic with a stable intraocular lens in the blind eye.
Normal cornea with good visualization of the anterior segment.
Normal anterior segment anatomy including the iris bed.
- General and metabolic inclusion criteria:
Male and female subjects ages 18 to 75 years of age and no history of non-compliance.
Clinical history compatible with T1D or T2D with or without insulin-dependence at the time of enrollment.
Stable renal function of native or transplanted kidney if applicable.
Ability to provide written informed consent.
Mentally stable and able to comply with the procedures of the study protocol.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Bascom Palmer Eye Institute Coordinator of this site? Confirm its status	Miami	United States	Recruiting
Diabetes Research Institute, University of Miami Miller School of Medicine Coordinator of this site? Confirm its status	Miami	United States	Recruiting

This page is information, not medical advice. Discuss any trial with your doctor.